The study will evaluate the efficacy and safety of amatuximab, a monoclonal antibody that targets mesothelin, when combined with the standard chemotherapy regimen pemetrexed plus cisplatin. The MORAb-009-201 study design is based on the exposure response results of the completed 89-patient MORAb-009-003 Phase 2 study.
